Bipolar disorder is a severe mental disorder that necessitates effective long-term treatment strategies. Clinically, lithium has demonstrated favorable outcomes in managing this condition. The inflammatory theory posits that bipolar disorder is influenced by an inflammatory response, and lithium is thought to mitigate this disorder by inhibiting such responses. In terms of the pharmacodynamics of blocking inflammatory mediators, lithium mainly acts on GSK-3β. Upon interaction with GSK-3β, lithium can suppress the gene expression of inflammatory mediators, subsequently reducing their secretion. This mechanism influences multiple downstream pathways, ultimately contributing to the therapeutic effects observed in bipolar disorder. Specifically, these pathways include the arachidonic acid pathway, nitric oxide synthase pathway, neurotransmitter pathway, and so on. This article reviews the pharmacodynamic targets and mechanisms of lithium, offering insights into the appropriate clinical application of lithium and the advancement of lithium pharmacotherapies.
AllenNJBarresBA (2009) Neuroscience: Glia—more than just brain glue. Nature457: 675–677.
2.
AkarsuSBoluAAydemirE, et al. (2018) The relationship between the number of manic episodes and oxidative stress indicators in bipolar disorder. Psychiatry Investig15: 514–519.
3.
ArangoVUnderwoodMDMannJJ (2020) Chapter 35 Serotonin brain circuits involved in major depression and suicide. Prog Brain Res136: 443–453.
4.
AshokAHMarquesTRJauharS, et al. (2017) The dopamine hypothesis of bipolar affective disorder: The state of the art and implications for treatment. Mol Psychiatry22: 666–679.
5.
BagettaGMassoudRRodinòP, et al. (1993) Systemic administration of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus of rats. Eur J Pharmacol237: 61–64.
6.
BaldessariniRJTondoLDavisP, et al. (2010) Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord8: 625–639.
7.
BeishuizenAThijsLG (2003) Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res9: 3–24.
8.
BerkMKapczinskiFAndreazzaAC, et al. (2011) Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev35: 804–817.
9.
BerkMWilliamsLJJackaFN, et al. (2013) So depression is an inflammatory disease, but where does the inflammation come from?BMC Med11: 200.
10.
BeurelEJopeR (2009) Glycogen synthase kinase-3 promotes the synergistic action of interferon-gamma on lipopolysaccharide-induced IL-6 production in RAW264.7 cells. Cell Signal21: 978–985.
11.
BosettiFRintalaJSeemannR, et al. (2002) Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol Psychiatry7: 845–850.
12.
BrownGCNeherJJ (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol41: 242–247.
13.
ButtsKAWeinbergJYoungAH, et al. (2011) Glucocorticoid receptors in the prefrontal cortex regulate stress-evoked dopamine efflux and aspects of executive function. Proc Natl Acad Sci108: 18459–18464.
14.
CapuronLNeurauterGMusselmanDL, et al. (2003) Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry54: 906–914.
15.
ChangMCJContrerasMARosenbergerTA, et al. (2010) Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: A possible common effect of mood stabilizers. J Neurochem77: 796–803.
16.
ChengXLiM (2024) The role of peripheral inflammation in cognitive impairments of bipolar disorder. Chinese J Nerv Ment Dis x50: 119–123.
17.
CryanJFDinanTG (2012) Mind-altering microorganisms: The impact of the gut microbiota on brain and behavior. Nat Rev Neurosci13: 701–712.
18.
DantzerRWalkerAK (2014) Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?J Neural Trans121: 925.
19.
EkdahlCT (2012) Microglial activation—tuning and pruning adult neurogenesis. Front Pharmacol3: 41.
20.
FaridhosseiniFTalaeiAShahiniN, et al. (2023) Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran. Int Clin Psychopharmacol38: 336–341.
21.
FriesGRWalss-BassCBauerME, et al. (2019) Revisiting inflammation in bipolar disorder[J]. Pharmacol Biochem Behav177: 12–19.
22.
García-ÁlvarezLCasoJRGarcía-PortillaMP, et al. (2018) Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls. Eur Psychiatry47: 50–59.
23.
GershonSChengappaKNRMalhiGS (2010) Lithium specificity in bipolar illness: A classic agent for the classic disorder. Bipolar Disord11: 34–44.
24.
GhoshSHaydenMS (2008) New regulators of NF-kappaB in inflammation. Nat Rev Immunol8: 837–848.
GirshkinLMathesonSLShepherdAM, et al. (2014) Morning cortisol levels in schizophrenia and bipolar disorder: A meta-analysis. Psychoneuroendocrinology49: 187–206.
27.
GoetzlEJAnSSmithWL (1995) Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. Faseb J9: 1051–1058.
28.
GouldTDPicchiniAMEinatH, et al. (2006) Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr Drug Targets7: 1399–1409.
29.
HaarmanBCRiemersma-Van der LekRFde GrootJC, et al. (2014) Neuroinflammation in bipolar disorder—A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun40: 219–225.
30.
HamdaniNBoukouaciWHalloucheMR, et al. (2015) Resolution of a manic episode treated with activated charcoal: Evidence for a brain-gut axis in bipolar disorder. Aust N Z J Psychiatry2015; 49: 1221–1223.
31.
HaroonEMillerAH (2016) Inflammation effects on brain glutamate in depression: Mechanistic considerations and treatment implications. Curr Top Behav Neurosci31: 173–198.
32.
HarryGJKraftAD (2012) Microglia in the developing brain: A potential target with lifetime effects. Neurotoxicology33: 191–206.
33.
HarveyAG (2008) Sleep and circadian rhythms in bipolar disorder: Seeking synchrony, harmony, and regulation. Am J Psychiatry165: 820–829.
34.
HoeflichKPLuoJRubieEA, et al. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature406: 86–90.
35.
IrwinMROlmsteadRCarrollJE (2016) Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry80: 40–52.
36.
Jiménez-FernándezSGurpeguiMDíaz-AtienzaF, et al. (2015) Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: Results from a meta-analysis. J Clin Psychiatry76: 1658–1667.
37.
JoshuaRRogerMI (2017) Bipolar disorder and immune dysfunction: Epidemiological findings, proposed pathophysiology and clinical implications. Brain Sci7: 144.
38.
JuruenaMFErorFCleareAJ, et al. (2020) The role of early life stress in HPA axis and anxiety. Adv Exp Med Biol1191: 141–153.
39.
KarmazynMMankuMSHorrobinDF (1978) Changes of vascular reactivity induced by low vasopressin concentrations: Interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology102: 1230–1236.
40.
KhandakerGMCousinsLDeakinJ, et al. (2015) Inflammation and immunity in schizophrenia: Implications for pathophysiology and treatment. Lancet Psychiatry2: 258–270.
41.
KokkosisAGTsirkaSE (2020) Neuroimmune mechanisms and sex/gender-dependent effects in the pathophysiology of mental disorders. J Pharmacol Exp Ther375: 175–192.
42.
KoriyamaYNakayamaYMatsugoS, et al. (2013) Anti-inflammatory effects of lipoic acid through inhibition of GSK-3β in lipopolysaccharide-induced BV-2 microglial cells. Neurosci Res77: 87–96.
43.
LačkovićMStojkovićTPantović StefanovićM, et al. (2023) 8-Iso-prostaglandin F2α as a potential biomarker in patients with unipolar and bipolar depression. Eur Rev Med Pharmacol Sci27: 11496–11507.
44.
LenazGD’AurelioMPichMM, et al. (2000) Mitochondrial bioenergetics in aging. Biochim Biophys Acta1459: 397–404.
45.
LeonardBE (2001) The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry25: 767–780.
46.
LeuchtSHelferBDoldM, et al. (2003) Lithium for schizophrenia. Cochrane Database Syst Rev3: CD003834.
47.
MahadikSPEvansDLalH (2001) Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry25: 463–493.
48.
MalhiGTaniousMDasP, et al. (2013) Potential mechanisms of action of lithium in bipolar disorder. CNS Drugs27: 135–153.
49.
MartinMRehaniKJopeRS, et al. (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol6: 777–784.
50.
McIntyreRSBerkMBrietzkeE, et al. (2020) Bipolar disorders. Lancet396: 1841–1856.
51.
McIntyreRS (2016) Sleep and inflammation: Implications for domain approach and treatment opportunities. Biol Psychiatry80: 9–11.
MrcpsychHCarvalhoAFMeyerJH, et al. (2020) Minocycline and celecoxib as adjunctive treatments for bipolar depression: A multicenter, factorial design randomized controlled trial. Lancet Psychiatry7: 515–527.
54.
MukherjeeDKrishnamurthyVBMillettCE, et al. (2017) Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. Bipolar Disord20: 27–34.
55.
MukherjeeDWeissenkampenJDWassermanE, et al. (2022) Dysregulated diurnal cortisol pattern and heightened night-time cortisol in individuals with bipolar disorder. Neuropsychobiology81: 51–59.
56.
MurphyDLDonnellyCMoskowitzJ (1973) Inhibition by lithium of prostaglandin E1 and norepinephrine effects on cyclic adenosine monophosphate production in human platelets. Clin Pharmacol Ther14: 810–814.
57.
MurriMBPrestiaDMondelliV, et al. (2015) The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology63: 327–342.
58.
MüllerNSchwarzMJDehningS, et al. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry11: 680–684.
59.
NahmanSBelmakerRAzabAN (2012) Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun18: 447–458.
60.
NassarAAzabAN (2014) Effects of lithium on inflammation. ACS Chem Neurosci5: 451.
61.
NeryFGMonkulESHatchJP, et al. (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol Clin Exp23: 87–94.
62.
NuttDJBlierP (2016) Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology. J Psychopharmacol30: 413–415.
63.
O’ConnellKSCoombesBJ (2021) Genetic contributions to bipolar disorder: Current status and future directions. Psychol Med51: 2156–2167.
64.
O’DonovanABahorikASidneyS, et al. (2021) Relationships of inflammation trajectories with white matter volume and integrity in midlife. Brain Behav Immun91: 81–88.
65.
OliveiraRMGuimarãesFSDeakinJF (2008) Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Brazil J Med Biol Res41: 333–341.
66.
PapageorgiouCGrapsaEChristodoulouNG, et al. (2001) Association of serum nitric oxide levels with depressive symptoms: A study with end-stage renal failure patients. Psychother Psychosom70: 216–220.
67.
PompiliMRihmerZInnamoratiM, et al. (2009) Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother9: 109–136.
68.
RayasamGVTulasiVKSodhiR, et al. (2010) Glycogen synthase kinase 3: More than a namesake. Br J Pharmacol156: 885–898.
69.
RheeSHPothoulakisCMayerEA (2009) Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol6: 306–314.
70.
RicciottiEFitzGeraldGA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol31: 986–1000.
SavaHHalukAHerkenH, et al. (2002) Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology45: 57–61.
73.
ScainiGAndrewsTLimaCNC, et al. (2021) Mitochondrial dysfunction as a critical event in the pathophysiology of bipolar disorder. Mitochondrion57: 23–36.
74.
SchwarczRBrunoJPMuchowskiPJ, et al. (2012) Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci13: 465–477.
75.
SessoGBrancatiGEMasiG (2023) Comorbidities in youth with bipolar disorder: Clinical features and pharmacological management. Curr Neuropharmacol21: 911–934.
76.
SimpsonDSPangJWeirA, et al. (2022) Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway. Immunity55: 423–441.e9.
77.
SmithWLGaravitoRMDeWittDL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem271: 33157–33160.
78.
StephensMACWandG (2012) Stress and the HPA axis: Role of glucocorticoids in alcohol dependence. Alcohol Res34: 468.
79.
StertzLMagalhãesPVKapczinskiF (2013) Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry26: 19–26.
80.
SudoNChidaYAibaY, et al. (2010) Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol558: 263–275.
81.
SuzukiEYagiGNakakiT, et al. (2001) Elevated plasma nitrate levels in depressive states. J Affect Disord63: 221–224.
82.
SwardfagerWRosenblatJDBenlamriM, et al. (2016) Mapping inflammation onto mood: Inflammatory mediators of anhedonia. Neurosci Biobehav Rev64: 148–166.
83.
van HorssenJvan SchaikPWitteM (2019) Inflammation and mitochondrial dysfunction: A vicious circle in neurodegenerative disorders?Neurosci Lett710: 132931.
84.
WangHMZhangTLiQ, et al. (2013) Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochem Int63: 345–353.
85.
WangJDunnAJ (1998) Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int33: 143.
86.
WuSZhouY (2024) Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: A narrative review. Ther Adv Psychopharmacol14: 20451253241227772.
87.
YanikMVuralHTutkunH, et al. (2004) The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci254: 43–47.
YathamLNKennedySHParikhSV, et al. (2018) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord20: 97–170.
90.
YavropoulouMPSfikakisPPChrousosGP (2023) Immune system effects on the endocrine system. In: FeingoldKRAnawaltBBlackmanMR, et al. (eds.) Endotext. South Dartmouth, MA: MDText.com, Inc.
91.
YoungAH (2014) The effects of HPA axis function on cognition and its implications for the pathophysiology of bipolar disorder. Harv Rev Psychiatry22: 331–333.
92.
YuFWangZTanakaM, et al. (2013) Posttrauma cotreatment with lithium and valproate: Reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. J Neurosurg119: 766–773.
93.
ZhangLMengHQ (2017) Advances in immunological research on bipolar disorder. Sichuan Mental Health30: 85–89.
94.
ZhuoCTianHChenG, et al. (2023) Low-dose lithium mono- and adjunctive therapies improve MK-801-induced cognitive impairment and schizophrenia-like behavior in mice—Evidence from altered prefrontal lobe Ca2+ activity. J Affect Disord337: 128–142.
95.
ZovettiNRossettiMGPerliniC, et al. (2023) Brain ageing and neurodegeneration in bipolar disorder. J Affect Disord323: 171–175.
